30/05/2023
Sandy trained clinically as a pharmaceutical physician. He leads a research group at the University of Oxford with interests in vaccine manufacturing and in translational development of novel vaccines, including against rabies and Epstein Barr virus.
He and his team developed the core of the process used to make the Oxford / AstraZeneca COVID-19 vaccine at large scale, and the model of internationally distributed manufacturing of the product using multiple existing facilities. Before AZ’s involvement in the programme, he established the CDMO consortium which scaled up production in the UK, and initiated technology transfer to major Indian & Chinese manufacturers.
He leads the University of Oxford Bioprocess & Analytical Development (‘BiPAD’) team, which bridges between innovator academics and GMP manufacturing facilities. He has a particular interest in reducing technical, IP and financial barriers to early-phase clinical trials and experimental medicine.